PCOS and Cholesterol: The Dyslipidaemia Pattern and What Changes It

What Does the PCOS Lipid Profile Actually Look Like?

Triglycerides run about 26 mg/dL higher and HDL-cholesterol about 6 mg/dL lower in women with PCOS than in matched women without it, according to a systematic review and meta-analysis of lipid levels pooling cross-sectional studies worldwide. LDL-cholesterol and non-HDL-cholesterol were also higher — by 12 mg/dL and 19 mg/dL — and both differences held even after matching PCOS and control groups on BMI, meaning body weight alone doesn’t explain the pattern.

Dyslipidemia is also common, not a rare complication, and the 2023 international guideline treats metabolic and cardiovascular risk factors — lipids included — as a standard part of PCOS care rather than something ordered only when weight or another symptom points toward it, a point covered in more depth further down this page. This article sits inside the weight-loss section, which is really about metabolic markers — insulin, glucose, lipids — rather than a number on a scale.

Read that pattern against what “high cholesterol” usually conjures. The general-population image is a high LDL number on its own. The PCOS pattern is smaller and more specific: triglycerides up, HDL down, LDL only moderately higher — the same triglyceride-HDL combination seen in insulin resistance generally, which tracks with the mechanism covered here.

Why Are Triglycerides Specifically the Marker to Watch?

Triglycerides sit closer to the insulin-resistance mechanism than any other number on a standard lipid panel, which is why this page leads with them rather than with total cholesterol. When cells resist insulin’s signal, the liver ends up packaging and releasing more triglyceride-rich particles into the blood, and those same particles are part of what drives HDL-cholesterol down and shifts LDL toward the smaller, denser form described further down this page. That is one connected process showing up as three separate numbers on a panel, not three unrelated findings — which is also why triglycerides and HDL tend to move together in trial data, even when a trial wasn’t designed to target lipids at all.

What Counts as High Cholesterol, in mg/dL and mmol/L?

A total cholesterol above 240 mg/dL (6.2 mmol/L) is classified as high by the reference thresholds most US, UK, Australian and Canadian labs still use, though the exact category boundaries below matter more than the single “high” cutoff for understanding where your own numbers sit.

These are general adult population thresholds, not PCOS-specific ones — no separate PCOS lipid cutoffs exist. That gap is exactly why Table 1 matters more than Table 2 for understanding PCOS risk specifically: someone can sit inside “normal” LDL-cholesterol by Table 2 and still carry the triglyceride-HDL pattern and particle-quality shift that Table 1 describes.

Why Is the PCOS Pattern Different From “High Cholesterol” in General?

Beyond the numbers in Table 1, the quality of LDL particles themselves changes in PCOS. Women with PCOS have “an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size,” according to a 2013 review of the condition’s lipid abnormalities — small, dense LDL particles are more able to penetrate artery walls than larger, buoyant ones carrying the same total cholesterol content. The same review also flagged elevated lipoprotein(a), an independent cardiovascular risk marker, and lower apolipoprotein A-I, a protein component of HDL linked to its protective effect — two markers a standard lipid panel doesn’t report at all. None of this shows up as a bigger number on a routine test; it shows up as a different, higher-risk composition inside a number that can look ordinary. If your total cholesterol and LDL-cholesterol have both come back “normal” but you still have PCOS’s triglyceride-and-HDL pattern from Table 1, that combination — not the LDL number alone — is what a clinician managing your cardiovascular risk actually needs to see.

What Actually Changes the Lipid Pattern in PCOS?

Metformin improved LDL-cholesterol significantly in overweight women with PCOS but left HDL, total cholesterol and triglycerides statistically unchanged, according to a 2020 meta-analysis of 12 randomized trials — a partial result, not a full correction of the pattern in Table 1. No supplement or medication trial reviewed for this page corrected all four markers at once. Dietary fibre has the most direct mechanistic link to the triglyceride and LDL side of the pattern; fibre and PCOS covers the amounts studied. The exercise and diet interventions with measured effects on insulin resistance are covered separately in treating insulin resistance in PCOS, since the same trials that move HOMA-IR often report lipid changes alongside it, even when lipids weren’t the primary target — the low-glycemic-index diet trials in that ranking, for instance, were measuring HOMA-IR and testosterone as primary outcomes, with any lipid shift reported as a secondary finding rather than the thing the trial was built to test. That distinction matters when you’re reading trial evidence yourself: a lipid result reported as secondary usually comes from a smaller, less-powered analysis than the trial’s main outcome, even inside the same paper.

Does Everyone With PCOS Have This Pattern?

No — and the evidence on this point is genuinely mixed, not just cautious. One study of 195 non-Hispanic white women with PCOS found LDL-cholesterol elevation was the predominant abnormality, independent of obesity, but that “the characteristic dyslipidemia of insulin resistance” — the low-HDL, high-triglyceride combination — was actually absent in that particular cohort; obese women with PCOS in that study had relatively elevated HDL-cholesterol, the opposite of the usual pattern. A separate Korean study found non-obese women with PCOS had no significant quantitative or qualitative change in LDL profile at all. Ethnicity, BMI category and which specific markers a study measured all shift which part of the pattern shows up, and by how much. That heterogeneity is a reason to get your own panel drawn rather than assume the averages in Table 1 describe you specifically — not a reason to skip the test.

Even within a single large study, the predictors only went so far. In the non-Hispanic white cohort above, age, BMI and PCOS status together accounted for no more than 25% of the variance in lipid levels between individuals — meaning roughly three-quarters of why any one person’s numbers land where they do was explained by something the study didn’t measure. That is a genuinely honest limit in this evidence, not a caveat added for comfort: population averages are the best tool available for describing a pattern, and a poor tool for predicting one specific person’s next lab result.

You may see this condition written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 medical organisations renamed it. The lipid pattern and thresholds above are unchanged by the name — this page uses PCOS because that’s still what most people search.

What to Ask For on Your Next Panel

Ask specifically for triglycerides, HDL, LDL and non-HDL-cholesterol together, not just a “total cholesterol” result — non-HDL-cholesterol in particular is calculated from the same panel but often left off a basic summary. If your results come back with LDL in the “normal” range on Table 2 but your triglycerides are elevated and your HDL is low, that combination is the pattern this page describes, worth naming explicitly when you discuss it with whoever is managing your care, alongside glucose screening, since both are drawn from the same blood.

None of this is a reason to treat a lipid panel as a verdict on how well you’re managing PCOS. The pattern in Table 1 shows up independent of BMI in pooled trial data, and the variance data above means most of what determines any one person’s numbers isn’t something a food diary or a walk schedule fully controls. The number is information for a conversation with a clinician about cardiovascular risk — not a score to correct through willpower.